Figure 3From: Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritisComparison of macroscopic and histological evaluations between the osteoarthritis (OA) and intravenous administration of bevacizumab in OA (OAB IV) rabbits (experiment 2). (A) Macroscopic articular cartilage appearance 4 weeks after anterior cruciate ligament transection (ACLT). (B) Macroscopic appearance 12 weeks after ACLT. Circles indicate osteophyte formation. (C) Osteophyte formation scores 4 and 12 weeks after ACLT. Data are expressed as mean ± SD (n = 8 knees). Safranin O staining of hyaline cartilage 4 weeks (D) and 12 weeks (E) after ACLT. (F) Osteoarthritis Research Society International histological score 4 and 12 weeks after ACLT. (G) Macroscopic synovia appearance 4 weeks after ACLT. (H) Representative synovial histology for OA group (left side) and OAB IV group (right side) stained with H&E. Higher magnifications of the image shown in (H) stained with HE (I) and Masson trichrome (J). Data are expressed as mean ± SD (n = 8 knees). *P <0.05 by the Mann-Whitney U-test. Bars = 1 mm (D, E, H); bars = 300 μm (I, J).Back to article page